The largest trial of tranexamic acid (TXA) ever performed has shed much-needed light on the drug’s cardiovascular effects in patients undergoing major noncardiac surgery, and the results are somewhat surprising.
The POISE-3 (PeriOperative ISchemic Evaluation-3) trial concluded that patients treated with TXA not only had significantly fewer serious bleeding events than those treated with placebo, but also did not suffer more cardiovascular injury.
“There is no question that TXA reduces